Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Dec 23, 2020 11:21am
142 Views
Post# 32169328

RE:RE:RE:RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"

RE:RE:RE:RE:RE:RE:RE:New Analyst Coverage: Thera "Speculative Buy"I believe in decency and honesty and I don't suggest THTX to engage in any dubious activities, my point is their strategy to support the valuation hasn't changed despite the arrival of the new CEO.
Let's face it the execution has been slow , the communication is confusing thus far.
If you really want to get the SP to appreciate you have to start at right end which is the retail, get the attention of mom and dad investors, therefore they need to engage with the average investor earn their trust, increase the demand/daily volume then go after institutional investors.
They first announced HIV NASH opportunity a year and half ago, last September they announced the shift to general NASH which was supposed to be submitted in few weeks and then radio silence!
nothing more than it will be submitted by end of the year as per IP.
point is they need to be more precise  and stop hiding behind words such as few weeks/imminent also they need to speed up as the progress has been far to slow, I get it they need to perfect the applications in order to enhance the success rate but while the competitors are progressing THTX has been far to slow.
I still struggle to understand why they don't think submission of both protocols is not material event for this company, maybe that is true for other companies with great track record but THTX needs to come out of hiding and market their programs in a proper manner so we get those investors which are not convinced atm.
<< Previous
Bullboard Posts
Next >>